Author/Authors :
Takamura، نويسنده , , Masaaki and Ichida، نويسنده , , Takafumi and Matsuda، نويسنده , , Yasunobu and Kobayashi، نويسنده , , Masaaki and Yamagiwa، نويسنده , , Satoshi and Genda، نويسنده , , Takuya and Shioji، نويسنده , , Kazuhiko and Hashimoto، نويسنده , , Satoru and Nomoto، نويسنده , , Minoru and Hatakeyama، نويسنده , , Katsuyoshi and Ajioka، نويسنده , , Yoichi and Sakamoto، نويسنده , , Michiie and Hirohashi، نويسنده , , Setsuo and Aoyagi، نويسنده , , Yutaka، نويسنده ,
Abstract :
Liver–intestine cadherin (LI-cadherin) is a recently identified member of the cadherin superfamily. We examined LI-cadherin expression in four human colorectal carcinoma cell lines and 45 human primary colorectal carcinomas using a monoclonal antibody against LI-cadherin. We also investigated the correlation between LI-cadherin expression and clinicopathologic parameters. Among the cell lines, LI-cadherin expression was detected in a differentiated phenotype, but not in dedifferentiated phenotypes. Among the 45 tumor samples, LI-cadherin expression was preserved in 28 (62%) and reduced in 17 (38%). Reduced LI-cadherin expression was significantly associated with a high tumor grade (P=0.015), lymphatic invasion (P=0.033), lymph node metastasis (P=0.015), and an advanced pTNM stage (P=0.033). These results suggest that analysis of LI-cadherin expression may help to indicate the biological aggressiveness of this malignancy.
Keywords :
Liver–intestine cadherin , Lymph node metastasis , immunohistochemistry , monoclonal antibody , colorectal carcinoma